Startups
Absci is the drug and target discovery company harnessing deep learning and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic candidates, and generate the cell lines to manufacture them in a single efficient process. Biotech and pharma innovators partner with us to create the next generation of protein-based drugs, including those that may be impossible to make with other technologies. Our goal is to enable the development of better medicines by Translating Ideas into Drugs™. For more information visit www.absci.com.
Overview
Location
United States, Washington, Vancouver
Employees
201-500
Phone
(503) 208-7882
Total raised
$217.4M
Founded date
2011
Investors 5
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Phoenix Venture Partners | phoenix-vp.com | |
| Columbia Ventures | colventures.com | |
| Tachyon Ventures | tachyon.vc | |
| Perceptive Advisors | perceptivelife.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Oct 20, 2020 | Funding round | $65M | |
| Jan 13, 2020 | Series D round | $15.4M | |
| May 30, 2018 | Series C round | $12M |
Mentions in press and media 43
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 3, 2026 | Diversity will define the next era of biotech infrastructure | |
| Aug 16, 2024 | A New Dawn in Cancer Research: AI and Funding Unite for Hope | In the battle against cancer, innovation is the sword and funding is the shield. Two recent developments highlight this truth: a groundbreaking collaboration between Absci Corporation and Memorial Sloan Kettering Cancer Center (MSK), and a ... |
| Aug 12, 2024 | Absci and MSK Collaborate on Generative AI Drug Discovery | What You Should Know: – Absci Corporation, a leader in generative AI drug creation, today announced a strategic collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop up to six novel cancer therapeutics. – By combining A... |
| May 20, 2024 | SynBioBeta 2024: From novel hosts to ‘tricking’ cells to be more productive… addressing the ‘scale-cost paradox’ in biomanufacturing | Since insulin produced by genetically engineered bacteria—rather than the pancreases of slaughtered animals—was first approved in 1982, the market for ‘biomanufactured’ products produced by microbial, animal, or plant cells has grown rapidl... |
| Apr 2, 2024 | Экономический анализ: как генеративный ИИ меняет производительность труда и перспективы профессий | На связи Алексей Мартынов и Денис Ларионов, мы продолжаем делиться актуальной аналитикой о генеративном ИИ. Предыдущую нашу статью с описанием текущего положения дел на рынке генеративного ИИ и прогнозом до 2032 года найдёте здесь . Для тех... |
| Mar 6, 2024 | Latest Updates of Viva Biotech's Portfolio Companies | HONG KONG, March 6, 2024 /PRNewswire/ -- Even with the ever-changing situation, technological innovation is still the most critical component for biopharmaceutical companies' long-term development. This continuous innovation keeps companies... |
| Feb 28, 2024 | Absci Announces $75M Public Offering to Fuel AI Drug Creation | What You Should Know: – Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock. – This IPO aims to support the advancement of A... |
| Dec 20, 2023 | Absci, PrecisionLife Partner to Develop AI-Enabled Drug Pipeline | What You Should Know: – Absci, a generative AI drug creation company, and PrecisionLife, a pioneer in computational biology for complex chronic diseases, have announced a powerful partnership to develop a joint portfolio of potential therap... |
| Dec 4, 2023 | Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer | What You Should Know: – Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer. – ... |
Show more
Reviews 0
FAQ about Absci
When was Absci founded?
Absci was founded in 2011.
How much funding has Absci raised?
Absci has raised $217.4M in total across 4 funding rounds.
What funding rounds has Absci raised?
Parsers VC lists 4 funding rounds of Absci, among them a funding round of $65M on Oct 20, 2020, a Series D round of $15.4M on Jan 13, 2020 and a Series C round of $12M on May 30, 2018.
Who has invested in Absci?
Parsers VC lists 5 investors of Absci, among them Phoenix Venture Partners, Columbia Ventures and Tachyon Ventures.
What has the press written about Absci?
Parsers VC has collected 43 articles mentioning Absci, among them “Diversity will define the next era of biotech infrastructure” (Mar 3, 2026) and “A New Dawn in Cancer Research: AI and Funding Unite for Hope” (Aug 16, 2024).
Is Absci still active?
Yes, Absci is active; its latest activity on Parsers VC dates from Aug 20, 2026.